ClinicalTrials.gg
CompletedNCT00624338APRIL-SLEUpdated Mar 14, 2016Results posted

Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)

A Phase 2/3 interventional study of Atacicept 75 mg and Atacicept 150 mg in Lupus Erythematosus, Systemic, sponsored by EMD Serono. Completed at 113 sites in 29 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2016-03-14.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
461
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany — 3 open to participants now, 4 under way, 3 of them phase 3. Lupus Erythematosus, Systemic · Merck KGaA, Darmstadt, Germany.

Enrollment
2nd of 12
461 · median 280
Started
2008
the only one that year
Phase 2/3
Only one
of the 12
Registered
1st of 12
by date

Among the 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany, this one is the 2nd largest by enrollment, is the only one that started in 2008, is the only one in phase 2/3, and was the 1st registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

3 of the 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany, or all of them as a file.
02

Study summary

This study is to evaluate the efficacy and safety of atacicept compared to placebo in preventing new flares in subjects with systemic lupus erythematosus (SLE) and to confirm the optimal dose of atacicept for treatment of subjects with SLE and gain information on the effect of atacicept on markers specific to its mechanism of action (MoA) and their correlation to disease activity/progression. Study medication will be administered through subcutaneous (under the skin) injections, beginning with twice weekly injections for the first 4 weeks, followed by once weekly doses for 48 weeks. Following the last treatment, a safety follow-up period of 24 weeks will be conducted.

03

Conditions studied

  • Lupus Erythematosus, Systemic

Keywords

  • Atacicept 75 and 150 mg
  • Placebo
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female 16 years of age or older
  • Disease history of at least six months meeting at least 4 out of the 11 American College of Rheumatology (ACR) criteria for SLE
  • Active SLE with at least one British Isles Lupus Assessment Group (BILAG) flare A or B at screening requiring a change in the dose of
  • Positive antinuclear antibody (ANA) or anti-double-stranded deoxyribonucleic acid (dsDNA) at screening
  • Female subjects must be willing to avoid pregnancy by using an adequate method of for 4 weeks prior to Study Day 1, during the trial and 24 weeks after the last dose of study medication
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Active moderate to severe glomerulonephritis (kidney impairment) as defined in the protocol
  • Active central nervous system SLE deemed to be severe/progressive and/or associated with significant cognitive impairment leading to inability to provide and/or comply with the protocol
  • Previous treatment with rituximab, abatacept, or belimumab
  • History of demyelinating disease such as multiple sclerosis (MS) or optic neuritis
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
461 participants (actual)

Study arms

  • Experimental
    Atacicept 75 mg

    Drug: Atacicept 75 mg

  • Experimental
    Atacicept 150 mg

    Drug: Atacicept 150 mg

  • Placebo comparator
    Placebo

    Other: Placebo Comparator

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing a New Flare as Defined by British Isles Lupus Assessment Group (BILAG) Score A or B

    A flare was defined as having an adjudicated BILAG A or B score in any of the 8 organ systems during treatment, or imputed for participants who had premature treatment discontinuation. Discontinuations due to sponsor termination of the atacicept 150 mg group were not imputed as flares in this analysis. The BILAG disease activity index evaluates systemic lupus erythematosus (SLE) activity in 8 organ systems, using a separate alphabetic score (A to E) assigned to each organ system defined as follows. BILAG A: Disease sufficiently active requiring disease-modifying treatment (prednisone greater than 20 mg daily or immunosuppressants); BILAG B: Disease less active than in "A", mild reversible problems requiring only symptomatic therapy such as antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), or prednisone less than 20 mg day; BILAG C: Stable mild disease; BILAG D: System previously affected but now inactive; BILAG E: System never involved.

    Time frame: From screening up to Week 52

Secondary outcomes

  1. Time to First New Flare as Defined by BILAG Score A or B

    A flare was defined as having an adjudicated BILAG A or B score in any of the 8 organ systems during treatment. Analysis was right-censored at Week 52. The hazard ratios and 95% confidence intervals were obtained from the Cox proportional hazards model. The 25th Percentile of time to new flare was reported using Kaplan-Meier estimates (Median was not reached). The BILAG disease activity index evaluates SLE activity in 8 organ systems, using a separate alphabetic score (A to E) assigned to each organ system defined as follows. BILAG A: Disease sufficiently active requiring disease-modifying treatment (prednisone greater than 20 mg daily or immunosuppressants); BILAG B: Disease less active than in "A", mild reversible problems requiring only symptomatic therapy such as antimalarials, NSAIDs, or prednisone less than 20 mg day; BILAG C: Stable mild disease; BILAG D: System previously affected but now inactive; BILAG E: System never involved.

    Time frame: From screening up to Week 52

  2. Percentage of Participants Experiencing a New Flare as Defined by BILAG Score A or B During Initial 24 Weeks

    A flare was defined as having an adjudicated BILAG A or B score in any of the 8 organ systems during treatment, or imputed for participants who had premature treatment discontinuation. The BILAG disease activity index evaluates SLE activity in 8 organ systems, using a separate alphabetic score (A to E) assigned to each organ system defined as follows. BILAG A: Disease sufficiently active requiring disease-modifying treatment (prednisone greater than 20 mg daily or immunosuppressants); BILAG B: Disease less active than in "A", mild reversible problems requiring only symptomatic therapy such as antimalarials, NSAIDs, or prednisone less than 20 mg day; BILAG C: Stable mild disease; BILAG D: System previously affected but now inactive; BILAG E: System never involved.

    Time frame: From screening up to Week 24

  3. Percentage of Participants Within Ordinal Response Categories for British Isles Lupus Assessment Group (BILAG) Flares

    Ordinal response categories have been defined as: 1) No BILAG A, no BILAG B, and completed treatment, 2) No BILAG A, at least 1 BILAG B during treatment period, and 3) At least 1 BILAG A during treatment period. The BILAG disease activity index evaluates SLE activity in 8 organ systems, using a separate alphabetic score (A to E) assigned to each organ system defined as follows. BILAG A: Disease sufficiently active requiring disease-modifying treatment (prednisone greater than 20 mg daily or immunosuppressants); BILAG B: Disease less active than in "A", mild reversible problems requiring only symptomatic therapy such as antimalarials, NSAIDs, or prednisone less than 20 mg day; BILAG C: Stable mild disease; BILAG D: System previously affected but now inactive; BILAG E: System never involved.

    Time frame: Week 52

  4. Mean Cumulative Corticosteroid Dose

    Time frame: Randomization up to Week 52

07

Results

Posted Mar 14, 2016
Limitations and caveats
Atacicept 150 mg group was discontinued on 2 February 2011 based on the recommendation from the Independent Data Monitoring Committee.

Participant flow

Participant flow — Overall Study
MilestoneAtacicept 75 mgAtacicept 150 mgPlacebo
Started159145157
Treated157144154
Completed11262111
Not completed478346
Withdrew: Adverse event141418
Withdrew: Lost to follow-up100
Withdrew: Lack of efficacy11314
Withdrew: Protocol violation332
Withdrew: Death020
Withdrew: Immunoglobulin less than 3gram per liter100
Withdrew: Termination of 150 mg group by sponsor0550
Withdrew: Other1559
Withdrew: Randomized but not treated213

Outcome measures

PrimaryPercentage of Participants Experiencing a New Flare as Defined by British Isles Lupus Assessment Group (BILAG) Score A or B

A flare was defined as having an adjudicated BILAG A or B score in any of the 8 organ systems during treatment, or imputed for participants who had premature treatment discontinuation. Discontinuations due to sponsor termination of the atacicept 150 mg group were not imputed as flares in this analysis. The BILAG disease activity index evaluates systemic lupus erythematosus (SLE) activity in 8 organ systems, using a separate alphabetic score (A to E) assigned to each organ system defined as follows. BILAG A: Disease sufficiently active requiring disease-modifying treatment (prednisone greater than 20 mg daily or immunosuppressants); BILAG B: Disease less active than in "A", mild reversible problems requiring only symptomatic therapy such as antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), or prednisone less than 20 mg day; BILAG C: Stable mild disease; BILAG D: System previously affected but now inactive; BILAG E: System never involved.

Time frame:
From screening up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing a New Flare as Defined by British Isles Lupus Assessment Group (BILAG) Score A or B
percentage of participantsAtacicept 75 mgAtacicept 150 mgPlacebo
Percentage of Participants Experiencing a New Flare as Defined by British Isles Lupus Assessment Group (BILAG) Score A or B57.3236.1153.25
Statistical analysis
  • Atacicept 75 mg vs Placebo · Regression, Logistic · p = 0.518 (Odds ratios were calculated from a logistic regression model adjusted for race and disease severity reported at screening.) · Odds ratio (or): 1.160 · 95% CI 0.74 to 1.82
  • Atacicept 150 mg vs Placebo · Regression, Logistic · p = 0.003 (Odds ratios were calculated from a logistic regression model adjusted for race and disease severity reported at screening.) · Odds ratio (or): 0.490 · 95% CI 0.31 to 0.78Atacicept 150 mg arm was discontinued prematurely. The analysis of 150 mg was considered post-hoc.
SecondaryTime to First New Flare as Defined by BILAG Score A or B

A flare was defined as having an adjudicated BILAG A or B score in any of the 8 organ systems during treatment. Analysis was right-censored at Week 52. The hazard ratios and 95% confidence intervals were obtained from the Cox proportional hazards model. The 25th Percentile of time to new flare was reported using Kaplan-Meier estimates (Median was not reached). The BILAG disease activity index evaluates SLE activity in 8 organ systems, using a separate alphabetic score (A to E) assigned to each organ system defined as follows. BILAG A: Disease sufficiently active requiring disease-modifying treatment (prednisone greater than 20 mg daily or immunosuppressants); BILAG B: Disease less active than in "A", mild reversible problems requiring only symptomatic therapy such as antimalarials, NSAIDs, or prednisone less than 20 mg day; BILAG C: Stable mild disease; BILAG D: System previously affected but now inactive; BILAG E: System never involved.

Time frame:
From screening up to Week 52
Reported as:
Number · days
Time to First New Flare as Defined by BILAG Score A or B
daysAtacicept 75 mgAtacicept 150 mgPlacebo
Time to First New Flare as Defined by BILAG Score A or B143 (112 to 226)310 (169 to NA)142 (87 to 197)
Statistical analysis
  • Atacicept 75 mg vs Placebo · Regression, Cox · p = 0.929 (Cox proportional hazards model was performed to calculate hazard ratios and adjusted for race and disease severity at time of screening.) · Hazard ratio (hr): 0.984 · 95% CI 0.69 to 1.40
  • Atacicept 150 mg vs Placebo · Regression, Cox · p = 0.009 (Cox proportional hazards model was performed to calculate hazard ratios and adjusted for race and disease severity at time of screening.) · Hazard ratio (hr): 0.562 · 95% CI 0.36 to 0.87Atacicept 150 mg arm was discontinued prematurely. The analysis of 150 mg was considered post-hoc.
SecondaryPercentage of Participants Experiencing a New Flare as Defined by BILAG Score A or B During Initial 24 Weeks

A flare was defined as having an adjudicated BILAG A or B score in any of the 8 organ systems during treatment, or imputed for participants who had premature treatment discontinuation. The BILAG disease activity index evaluates SLE activity in 8 organ systems, using a separate alphabetic score (A to E) assigned to each organ system defined as follows. BILAG A: Disease sufficiently active requiring disease-modifying treatment (prednisone greater than 20 mg daily or immunosuppressants); BILAG B: Disease less active than in "A", mild reversible problems requiring only symptomatic therapy such as antimalarials, NSAIDs, or prednisone less than 20 mg day; BILAG C: Stable mild disease; BILAG D: System previously affected but now inactive; BILAG E: System never involved.

Time frame:
From screening up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing a New Flare as Defined by BILAG Score A or B During Initial 24 Weeks
percentage of participantsAtacicept 75 mgAtacicept 150 mgPlacebo
Percentage of Participants Experiencing a New Flare as Defined by BILAG Score A or B During Initial 24 Weeks40.1328.4735.06
Statistical analysis
  • Atacicept 75 mg vs Placebo · Regression, Logistic · p = 0.412 (Odds ratios were calculated from a logistic regression model, adjusted for race and disease severity reported at screening.) · Odds ratio (or): 1.215 · 95% CI 0.76 to 1.94
  • Atacicept 150 mg vs Placebo · Regression, Logistic · p = 0.198 (Odds ratios were calculated from a logistic regression model, adjusted for race and disease severity reported at screening.) · Odds ratio (or): 0.722 · 95% CI 0.44 to 1.19Atacicept 150 mg arm was discontinued prematurely. The analysis of 150 mg was considered post-hoc.
SecondaryPercentage of Participants Within Ordinal Response Categories for British Isles Lupus Assessment Group (BILAG) Flares

Ordinal response categories have been defined as: 1) No BILAG A, no BILAG B, and completed treatment, 2) No BILAG A, at least 1 BILAG B during treatment period, and 3) At least 1 BILAG A during treatment period. The BILAG disease activity index evaluates SLE activity in 8 organ systems, using a separate alphabetic score (A to E) assigned to each organ system defined as follows. BILAG A: Disease sufficiently active requiring disease-modifying treatment (prednisone greater than 20 mg daily or immunosuppressants); BILAG B: Disease less active than in "A", mild reversible problems requiring only symptomatic therapy such as antimalarials, NSAIDs, or prednisone less than 20 mg day; BILAG C: Stable mild disease; BILAG D: System previously affected but now inactive; BILAG E: System never involved.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Within Ordinal Response Categories for British Isles Lupus Assessment Group (BILAG) Flares
percentage of participantsAtacicept 75 mgAtacicept 150 mgPlacebo
No BILAG A, no BILAG B, and completed treatment52.360.552.9
No BILAG A, at least 1 BILAG B in treatment period39.828.938.2
At least 1 BILAG A in treatment period7.810.58.8
SecondaryMean Cumulative Corticosteroid Dose
Time frame:
Randomization up to Week 52
Reported as:
Mean · mg
Mean Cumulative Corticosteroid Dose
mgAtacicept 75 mgAtacicept 150 mgPlacebo
Mean Cumulative Corticosteroid Dose2456.79 ± 1029.872018.87 ± 1062.612624.02 ± 812.44

Adverse events

Collected over Baseline up to 76 weeks (end of follow-up of the study). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atacicept 75 mg—30/157 (19.1%)129/157 (82.2%)
Atacicept 150 mg—23/144 (16%)120/144 (83.3%)
Placebo—27/154 (17.5%)118/154 (76.6%)
Most frequent serious events
Showing 10 of 116
Most frequent serious events
EventAtacicept 75 mgAtacicept 150 mgPlacebo
PneumoniaInfections and infestations5/1573/1442/154
Upper respiratory tract infectionInfections and infestations2/1572/1440/154
Pulmonary alveolar haemorrhageRespiratory, thoracic and mediastinal disorders0/1572/1440/154
Urinary tract infectionInfections and infestations1/1570/1442/154
Septic shockInfections and infestations0/1570/1442/154
Myocardial infarctionCardiac disorders1/1570/1442/154
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders0/1570/1442/154
HeadacheNervous system disorders0/1570/1442/154
Cervical dysplasiaReproductive system and breast disorders0/1570/1442/154
BronchitisInfections and infestations2/1570/1440/154
Most frequent other events
Showing 10 of 18
Most frequent other events
EventAtacicept 75 mgAtacicept 150 mgPlacebo
HeadacheNervous system disorders31/15717/14423/154
Upper respiratory tract infectionInfections and infestations24/15727/14424/154
Urinary tract infectionInfections and infestations22/15723/14417/154
Injection site reactionGeneral disorders16/15722/1443/154
NasopharyngitisInfections and infestations21/15716/14411/154
Injection site erythemaGeneral disorders10/15716/1440/154
Back painMusculoskeletal and connective tissue disorders14/1575/1448/154
DiarrhoeaGastrointestinal disorders9/1575/14413/154
BronchitisInfections and infestations12/15712/1446/154
NauseaGastrointestinal disorders11/1577/1446/154

Baseline characteristics

Intent-to-treat (ITT) population included all the randomized participants, regardless of whether they received treatment.

Age, Continuous
Age, Continuous(years)Atacicept 75 mgAtacicept 150 mgPlaceboTotal
Mean39.1 ± 12.039.0 ± 12.839.0 ± 12.139.0 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Atacicept 75 mgAtacicept 150 mgPlaceboTotal
Female148134148430
Male1111931
08

Study locations

113 sites
  • Division of Clinical Immunology and Rheumatology - UAB
    Birmingham, Alabama 35249-7201, United States
  • Stanford University
    Palo Alto, California, United States
  • Research Site
    San Diego, California, United States
  • Inland Rheumatology Clinical Trials Inc
    Upland, California, United States
  • Research Site
    Jacksonville, Florida, United States
  • Research Site
    Boise, Idaho, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • US Local Medical Information
    Rockland, Massachusetts 02370, United States
  • Wayne State University
    Detroit, Michigan 48201, United States
  • Justus J. Fiechtner, MD, MPH
    Lansing, Michigan 48910, United States
  • SUNY Health Science Center at Brooklyn
    Brooklyn, New York, United States
  • Feinstein Institute for Medical Research
    Manhasset, New York 11030, United States
  • Hospital for Special Surgey
    New York, New York 10021, United States
  • Research Site
    New York, New York, United States
  • Research Site
    Cincinnati, Ohio, United States
  • University of Cincinnati Medical Center, Division of Immunology
    Cincinnati, Ohio, United States
  • Research Site
    Temple, Texas, United States
  • Virginia Mason Medical Center
    Seattle, Washington, United States
  • Research Site
    Buenos Aires, Argentina
  • Research Site
    Cordoba, Argentina
  • Research Site
    Quilmes, Argentina
  • Research Site
    San Juan, Argentina
  • Research Site
    Tucuman, Argentina
  • Research Site
    Cairns, Australia
  • Research Site
    Clayton, Victoria, Australia
  • Research Site
    Sunshine Coast, Queensland, Australia
  • Research Site
    Woodville S.A., Australia
  • Research Site
    Wein, Austria
  • Research Site
    Sofia, Bulgaria
  • Research Site
    Osijek, Croatia
  • Research Site
    Rijeka, Croatia
  • Research Site
    Split, Croatia
  • Research Site
    Zagreb, Croatia
  • Research Site
    Prague, Czech Republic
  • Research Site
    Bordeaux Pessac, France
  • Research Site
    Lille, France
  • Research Site
    Montpelier Cedex, France
  • Research Site
    Paris, France
  • Research Site
    Strasbourg, France
  • Research Site
    Toulouse, France
  • Research Site
    Berlin, Germany
  • Research Site
    Erlangen, Germany
  • Research Site
    Hanover, Germany
  • Research Site
    Heidelberg, Germany
  • Research Site
    Herne, Germany
  • Research Site
    Munchen, Germany
  • Research Site
    Munster, Germany
  • Research Site
    Athens, Greece
  • Research Site
    Thessaloniki, Greece
  • Research Site
    Secunderabad, Andhra Pradesh, India
  • Research Site
    Haifa, Israel
  • Research Site
    Jerasalem, Israel
  • Research Site
    Petah-Tikva, Israel
  • Research Site
    Tel Aviv, Israel
  • Research Site
    Gyeonggi-do, Korea, Republic of
  • Research Site
    Seoul, Korea, Republic of
  • Research Site
    Riga, Latvia
  • Research Site
    Beirut, Lebanon
  • Research Site
    Kaunas, Lithuania
  • Research Site
    Vilnius, Lithuania
  • Research Site
    Kuala Lumpur, Malaysia
  • Research Site
    Perak, Malaysia
  • Research Site
    Seremban, Malaysia
  • Research Site
    Guadalajara Jalisco, Mexico
  • Research Site
    Tijuana, BC, Mexico
  • Research Site
    Amsterdam, Netherlands
  • Research Site
    Leiden, Netherlands
  • Research Site
    Maastricht, Netherlands
  • Research Site
    Angeles City, Pampanga, Philippines
  • Research Site
    Davao, Philippines
  • Research Site
    Iloilo, Philippines
  • Research Site
    Las Pinas, Philippines
  • Research Site
    Manila, Philippines
  • Research Site
    Bialystok, Poland
  • Research Site
    Gdańsk, Poland
  • Research Site
    Krakow, Poland
  • Research Site
    Lublin, Poland
  • Research Site
    Szczecin, Poland
  • Research Site
    Torun, Poland
  • Research Site
    Warsawa, Poland
  • Research Site
    Kemerovo, Russian Federation
  • Research Site
    Petrozavodsk, Russian Federation
  • Research Site
    Ryazan, Russian Federation
  • Research Site
    Saratov, Russian Federation
  • Research Site
    St Petersburg, Russian Federation
  • Research Site
    Tula, Russian Federation
  • Research Site
    Yaroslavl, Russian Federation
  • Research Site
    Belgrade, Serbia
  • Research Site
    Niska Banja, Serbia
  • Research Site
    Novi Beograd, Serbia
  • Research Site
    Cape Town, South Africa
  • Research Site
    Durban, South Africa
  • Research Site
    Panorama, Western Cape, South Africa
  • Research Site
    Parlow, Western Cape, South Africa
  • Research Site
    Pinelands, South Africa
  • Research Site
    Stellenbosch, Western Cape, South Africa
  • Research Site
    Barcelona, Spain
  • Research Site
    Madrid, Spain
  • Research Site
    Malaga, Spain
  • Research Site
    Santiago de Compostela, Spain

Showing the first 100 of 113 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015 Nov;74(11):2006-15. doi: 10.1136/annrheumdis-2013-205067. Epub 2014 Jun 20. Erratum In: Ann Rheum Dis. 2016 May;75(5):946. doi: 10.1136/annrheumdis-2013-205067corr1. PubMed 24951103 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Apr 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2008
First posted
Feb 27, 2008
Start
Jan 2008
Primary completionActual
Apr 2012
CompletionActual
Oct 2012
Results first posted
Mar 14, 2016
Last update
Mar 14, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00624338
Lead sponsor
EMD Serono
Responsible party
Sponsor
First posted
Feb 27, 2008
Start date
Jan 2008
Primary completion
Apr 2012
Completion
Oct 2012
Results posted
Mar 14, 2016
Last update
Mar 14, 2016

Study contacts

Medical Responsible
study director · Merck KGaA, Darmstadt, Germany
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein

Start the discussion